Clinical trial
An Open-Label, Multiple-Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BG9588 (Anti-CD40L Antibody) in Subjects With Proliferative Lupus Glomerulonephritis (SLE-GN)
NCT00001789 is registered in ClinicalTrials.gov with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multiple-Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BG9588 (Anti-CD40L Antibody) in Subjects With Proliferative Lupus Glomerulonephritis (SLE-GN)
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 1999
- Completion date
- May 31, 2000
- Enrollment
- 20
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.